title: [Usefulness of G-CSF in pediatric high risk cancer patients with fever and neutropenia].
abstract: Chemotherapy associated febrile neutropenia is an important cause of morbidity and mortality in pediatric patients with cancer. The use of granulocyte-colony stimulating factor (G-CSF) post chemotherapy decreases the risk of infectious complications but its efficacy during the febrile neutropenic episode remains controversial. Thirty five episodes of high-risk febrile neutropenia were randomized into two treatment arms, 18 received antibiotics and G-CSF (group A) and 17 received antibiotics only upon admission (group B). Both groups were comparable in terms of demographic and clinical characteristics. No significant differences between groups were found in duration of hospitalization (mean group A 7 vs group B 8 days), antibiotic treatment (mean 7 vs 8 days), fever (3 vs 2 days), nor of neutropenia (4 vs 3 days). One patient in group A died after RSV infection. Considering these results and a literature review, we propose that G-CSF should not be recommended in children during the course of their febrile neutropenic episode.
authors.affiliation: Unidad de Hemato-Oncología, Hospital de Niños Roberto del Río, Santiago, Chile. rodriguez@med.uchile.cl
authors.forename: Natalie
authors.initials: N
authors.lastname: Rodríguez Z
authors.forename: Juan
authors.initials: J
authors.lastname: Tordecilla C
authors.forename: Myriam
authors.initials: M
authors.lastname: Campbell B
authors.forename: Pilar
authors.initials: P
authors.lastname: Joannon S
authors.forename: Carlos
authors.initials: C
authors.lastname: Rizzardini L
authors.forename: Verónica
authors.initials: V
authors.lastname: Soto A
authors.forename: Patricia
authors.initials: P
authors.lastname: Verdugo L
mesh_terms: D000293:Adolescent; D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D000970:Antineoplastic Agents / Q000009:adverse effects*; D002648:Child; D002675:Child, Preschool; D005260:Female; D005334:Fever / Q000139:chemically induced / Q000188:drug therapy*; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use*; D006801:Humans; D007223:Infant; D007902:Length of Stay; D008297:Male; D009369:Neoplasms / Q000188:drug therapy*; D009503:Neutropenia / Q000139:chemically induced / Q000188:drug therapy*; D011446:Prospective Studies; D018570:Risk Assessment; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D000900:Anti-Bacterial Agents; D000970:Antineoplastic Agents; D016179:Granulocyte Colony-Stimulating Factor